Featured News
Propelling Breakthrough Gene Therapy Closer to Patients in Need
Manufacturing a First-in-Class Gene Therapy for Canavan Disease
Setting a new standard in viral vector innovation, Myrtelle has established a strategic partnership with two global leaders in gene therapy infrastructure, Charles River and Viralgen, leveraging GMP plasmid manufacturing and analytical excellence at our Keele, UK plasmid center of excellence.
In a press release, Myrtelle, a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, announced the manufacturing launch of its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD).
This landmark achievement propels the developer's breakthrough therapy closer to market and patients who urgently need it.
Adrian Stecyk, CEO, Myrtelle, commented: "This is a transformative moment for Myrtelle and the entire Canavan disease community. Initiating commercial manufacturing represents the culmination of our bold vision – to translate deep scientific innovation into real-world therapies. With Charles River and Viralgen as our partners, we are poised to deliver a life-changing treatment with precision, scalability, and speed."
Regulators have recognized the promise of Myrtelle's platform, granting distinctions that include:
- FDA: RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track designations
- EMA: Orphan Drug Designation and ATMP classification
- MHRA: Innovative Licensing and Access Pathway (ILAP) status
Furthermore, MYR-101 has been selected to participate in the FDA's Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program, an initiative to accelerate the development of treatments for serious rare diseases by enhancing regulatory communication and flexibility.
Manufacturing QC for Plasmid Critical Starting Materials
In today's evolving advanced therapies ecosystem, plasmid DNA retains its common role as a critical starting material for a range of advanced therapeutic modalities, laying the foundations for mRNA and CGT production.
Watch Webinar
Understanding Canavan Disease
Canavan disease is a fatal childhood genetic brain disease caused by mutations in the ASPA gene. The condition is present from birth, but signs may not be noticeable until several months later, when symptoms begin to develop. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge. Most affected children develop life-threatening complications by around 10 years of age, and currently, only palliative treatments are available.
Myrtelle's gene therapy, MYR-101, is engineered with a unique tropism for oligodendrocytes (the myelin-producing cells compromised in Canavan disease) and has been designed to directly address the genetic root of the disorder by restoring ASPA enzyme function and supporting healthy brain development.
This targeted approach has the potential to halt disease progression and enable neural repair through remyelination.
"When every day, every hour, every minute makes a difference in saving lives, the Charles River team is excited and privileged to continue to support Myrtelle at this pivotal stage," added Kerstin Dolph, CSVP Global Manufacturing. "Myrtelle's groundbreaking program exemplifies the progress gene therapy has made from concept toward commercial reality – and we’re proud to be part of that journey, bringing hope to the patients and families affected by Canavan disease."
With gene therapy manufacturing underway in preparation for commercialization, Myrtelle is offering hope to patients and families worldwide, moving toward its goal of delivering the first approved therapy for Canavan disease.
For more information on our integrated plasmid DNA, viral vector, and cell therapy development and manufacturing platforms and services, please visit Cell and Gene Therapy CDMO Solutions.